Pancreatic Neuroendocrine Tumors Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Pancreatic Neuroendocrine Tumors Epidemiology Forecast Report Coverage

Expert Market Research's “Pancreatic Neuroendocrine Tumors Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of pancreatic neuroendocrine tumors. It projects the future incidence and prevalence rates of pancreatic neuroendocrine tumors cases across various populations. The study covers age, gender, and type as major determinants of the pancreatic neuroendocrine tumors population. The report highlights patterns in the prevalence of pancreatic neuroendocrine tumors over time and projects future trends based on multiple variables.

Pancreatic Neuroendocrine Tumors Understanding: Disease Overview

Pancreatic neuroendocrine tumors (pNETs) arise from hormone-producing islet cells of the pancreas and represent a rare, heterogeneous group of neoplasms. They may be functional, secreting hormones such as insulin, gastrin, or glucagon, or non-functional, detected incidentally during imaging. pNETs are typically indolent but can metastasize, especially to the liver. The disease’s pathogenesis is associated with genetic mutations such as MEN1 and DAXX/ATRX alterations. Diagnosis relies on biochemical markers, imaging, and histopathology, with disease heterogeneity contributing to variable prognoses and management complexities.

Pancreatic Neuroendocrine Tumors Epidemiology Perspective

The pancreatic neuroendocrine tumors epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the pancreatic neuroendocrine tumors epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for pancreatic neuroendocrine tumors and their trends. The pancreatic neuroendocrine tumors detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Global registry analyses estimate the incidence of pancreatic neuroendocrine tumors (pNETs) at approximately 0.3-0.8 cases per 100,000 person-years, with higher detection rates linked to improved imaging and reporting systems.
• Median age typically mid-50s to early-60s (commonly reported ~55-62 years).
• Average age at diagnosis is around 60 years in many series.
• Recent studies indicate a nearly equal sex distribution in pancreatic neuroendocrine tumors, though certain cohorts report a slight male predominance, reflecting minimal gender-based variation in disease occurrence.

Read more about this report - Request a Free Sample

Country-wise Pancreatic Neuroendocrine Tumors Epidemiology Segment

The pancreatic neuroendocrine tumors epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In a United States study using the Surveillance, Epidemiology, and End Results (SEER) database (1973-2000), the crude annual incidence was about 2.2 per million (≈0.22 per 100,000). Overall, it was 1.8 per million in females, 2.6 per million in males. More recently (2000-2016), another US study found the annual incidence rose from ~0.27 per 100,000 to ~1.00 per 100,000. Many population-based studies report that the incidence of pNETs is less than 1 case per 100,000 persons per year in Europe and Asia.

Pancreatic Neuroendocrine Tumors: Treatment Overview

Treatment for pancreatic neuroendocrine tumors is determined by tumor grade, stage, and functionality. Surgical resection remains the cornerstone for localized disease, while advanced or metastatic tumors may require somatostatin analogs such as octreotide or lanreotide for symptom control and tumor stabilization. Targeted therapies like everolimus and sunitinib have demonstrated survival benefits in progressive pNETs. Peptide receptor radionuclide therapy (PRRT) using lutetium-177 DOTATATE offers additional options for refractory cases. Multidisciplinary management combining surgery, systemic therapy, and surveillance optimizes patient outcomes.

Key Questions Answered

• What are the key findings of pancreatic neuroendocrine tumors epidemiology in the 8 major markets?
• What will be the total number of patients with pancreatic neuroendocrine tumors across the 8 major markets during the forecast period?
• What was the country-wise pancreatic neuroendocrine tumors epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of pancreatic neuroendocrine tumors during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of pancreatic neuroendocrine tumors during the forecast period of 2026-2035?
• What are the currently available treatments for pancreatic neuroendocrine tumors?
• What are the disease risks, signs, symptoms, and unmet needs of pancreatic neuroendocrine tumors?

Scope of the Pancreatic Neuroendocrine Tumors Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of pancreatic neuroendocrine tumors based on several factors.
• Pancreatic Neuroendocrine Tumors Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The pancreatic neuroendocrine tumors report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Pancreatic Cancer Drug Pipeline Analysis

Pancreatic Neuroendocrine Tumors Pipeline Analysis